Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
Company: Kairos Pharma, LTD.
Filing Date: May 18, 2026
Reporting Period: Current report for events occurring on May 18, 2026.
Event: Issuance of a new investor presentation and participation in the 2026 LD Micro Invitational XVI in Los Angeles, CA.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific filing. The primary activity is the dissemination of an investor presentation.
Guidance, Outlook, and Management Commentary
- Management Action: CEO John Yu presented an update on the Company's clinical program and partnering activities at the LD Micro Invitational.
- Documentation: An investor presentation (Exhibit 99.1) was furnished with this filing.
- Legal Status: The information in Item 8.01 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act; it is not incorporated by reference into other filings.
Investor Verification Checklist
- Review the attached Investor Presentation (Exhibit 99.1) for specific details on clinical program progress and partnering activities.
- Verify the content of the presentation on the company website (www.kairospharma.com).
- Note that the presentation materials are not legally "filed" for liability purposes under Section 18 of the Exchange Act.